Eli Lilly's innovative drugs have been included in China's inaugural private insurance catalog, a move set to enhance sales prospects for advanced, high-cost treatments. The list, which also features medicines from Pfizer and Johnson & Johnson, is designed for drugs often considered too expensive for the state's national insurance but recommended for commercial health coverage. This development provides a new market channel for treatments targeting conditions like cancer and Alzheimer's. The inclusion is significant for global drugmakers as it may allow them to sell products at higher prices than what is typically negotiated under the national program, potentially bolstering profit margins. This new catalog aims to increase the role of commercial insurance in funding innovative medicines. Concurrently, Lilly's diabetes treatment, Mounjaro, was added to China's updated National Reimbursement Drug List (NRDL), with both changes taking effect on January 1.